WEBULL
WebtradeDownload

Is Cencora (COR) Undervalued On Its New Cell And Gene Therapy Push?

Simply Wall St · 2d ago

What Cencora’s New Cell and Gene Therapy Service Means For Investors

Cencora (COR) has launched a Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions, targeting health systems that want support building and scaling programs around these complex treatments.

The move lands in a market where more than 35 cell and gene therapies have FDA approval and over 1,700 clinical trials are active globally. Many target conditions with larger patient groups, which can raise operational demands for hospitals and specialty pharmacies.

Health system readiness currently looks limited. Only 4% of pharmacy leaders surveyed in a recent report described their organizations as fully prepared to integrate these therapies into routine care, pointing to both logistical and financial friction.

Cencora’s new offer aims to plug that gap through a bundled set of services that address financial planning, operational setup and future program expansion. For investors, the announcement adds another data point on how the distributor positions around complex specialty therapies.

  • Financial confidence, including market assessments, therapy specific financial considerations, reimbursement mechanics and site of care choices.
  • Operational readiness, through program launch or expansion support, readiness assessments, gap analysis, governance design and workflow planning.
  • Scalable growth, by helping health systems build repeatable operating models that coordinate strategy, finance, clinical operations, pharmacy and patient access teams.

The service also links into Cencora’s broader offerings across the cell and gene therapy product lifecycle. The group already provides commercialization support for developers, specialty distribution and solutions that focus on reliable access across different care settings.

Accelerate Pharmacy Solutions adds another layer. It combines Cencora’s pharmacy and supply chain expertise with patient delivery capabilities, which may matter for investors tracking how the business positions around advanced therapies that often involve cold chain logistics and complex reimbursement.

For context, Cencora reported revenue of US$332.8b and net income of US$2.6b on the latest available figures. The stock last closed at US$323.29 on 11 September 2026, with the share price up over the past month and the past 3 months and lower year to date.

Over longer periods, the total return over the past year, past 3 years and past 5 years has been positive. That provides some history on how the market has treated the ticker while management has expanded both U.S. Healthcare Solutions and International Healthcare Solutions segments.

Business mix still leans heavily toward the United States. U.S. Healthcare Solutions accounted for about US$300.1b of segment revenue while International Healthcare Solutions contributed roughly US$32.3b, with Segment Adjustment and Intersegment Eliminations making up the rest.

Recent price action has been mixed. The share price has eased over the past day and year to date. However, a 30 day share price return of 3.0% and a 90 day share price return of 16.7% point to momentum building again as Cencora rolls out new services and attends major healthcare conferences. A 1 year total shareholder return of 12.3% and a 5 year total shareholder return approaching 3x reflect how the market has historically responded to its broader expansion efforts.

Spot similar healthcare distributors and advanced-therapy plays by scanning the hand picked list of solid balance sheet and fundamentals (22 results).

Cencora now trades at US$323.29, while both analyst targets and intrinsic value estimates sit higher. This raises the question of where fair value might reasonably cluster within that spread.

Most Popular Narrative: 13% Undervalued

Cencora’s most followed valuation storyline pegs fair value around $372.58, comfortably above the last close at $323.29, which puts the new cell and gene therapy service into a wider capital allocation and growth context.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

See why 27 investors see Cencora as 13% undervalued.

This narrative uses a 7.24% discount rate and assumes revenue growth of about 5.8% a year with profit margins edging higher over time. Together, these inputs support a fair value estimate near $372.58. Against a market price of $323.29, that implies Cencora trades at a meaningful discount in this framework while still relying on moderate growth rather than aggressive assumptions.

The thesis leans heavily on specialty drug demand, earnings growth resilience and continued buybacks. It also flags pressures such as tighter regulation, high volume categories that contribute less to profit and weaker international logistics. Investors weighing the new Cell and Gene Therapy Enablement service can use those same drivers and risks as a checklist when judging how much weight to give today’s valuation gap.

Result: Fair Value of $372.58 (UNDERVALUED)

Still, Cencora’s story can change quickly if lower-fee generics compress distribution margins or if international specialty logistics continue to weigh on segment profitability.

Find out about the key risks to this Cencora narrative.

Next Steps

Mixed signals across Cencora’s service launches and valuation views only matter if you put them in your own context and move decisively. To pressure test the upside story against the possible downsides in one place, start by reviewing the 4 key rewards and 2 important warning signs.

Looking for more Cencora style investment ideas?

If you stop with Cencora, you miss the wider opportunity set. Use the Simply Wall St screener to surface fresh ideas that fit your own risk and return preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.